<DOC>
	<DOCNO>NCT00137449</DOCNO>
	<brief_summary>To evaluate antitumor activity SU011248 advance , imatinib mesylate-resistant gastrointestinal stromal tumor ( GIST ) administer continuous daily dosing schedule</brief_summary>
	<brief_title>Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor</brief_title>
	<detailed_description>Subjects experience clinical benefit 1 year study offer continued treatment SU011248 separate protocol .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histopathologically proven diagnosis malignant GIST amenable standard therapy . Failed prior treatment imatinib mesylate , define either progression disease ( accord Response Evaluation Criterion Solid Tumors ( RECIST ) World Health Organization ( WHO ) criterion ) , significant toxicity treatment imatinib mesylate preclude treatment . Intolerance prior imatinib mesylate therapy define follow : Lifethreatening adverse event ( ie , Grade 4 ) dose ( attempt dose reduce rechallenge require ) Unacceptable toxicity induce moderate dose ( eg , 400 mg/day ) , specifically , Grade 2 toxicity unacceptable patient ( nausea ) persist despite standard countermeasure Evidence unidimensionally measurable disease . Previous treatment SU011248 clinical trial . Diagnosis second malignancy within last 3 year , except basal cell carcinoma , squamous cell skin cancer , situ carcinoma , adequately treat evidence recurrent disease 12 month . History known brain metastasis , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease . Any follow within 12 month prior start study treatment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . Ongoing cardiac dysrhythmias grade 2 , atrial fibrillation grade , QTc interval &gt; 450 msec male &gt; 470 msec female . Hypertension could control medication ( &gt; 150/100 mm/Hg despite optimal medical therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>